Service d'imagerie pédiatrique et prénatale, Hôpital Timone Enfants, 264 Rue Sainte Pierre, 13385, Marseille Cedex 05, France.
Skeletal Radiol. 2012 Sep;41(9):1141-9. doi: 10.1007/s00256-012-1360-2. Epub 2012 Feb 9.
Preoperative diffusion-weighted MRI (DW-MRI) has been described as an efficient method to differentiate good and poor responders to chemotherapy in osteosarcoma patients. A DW-MRI performed earlier during treatment could be helpful in monitoring chemotherapy.
To assess the accuracy of DW-MRI in evaluating response to chemotherapy in the treatment of osteosarcoma, more specifically at mid-course of treatment.
This study was carried out on a prospective series of adolescents treated for long-bone osteosarcoma. MR examinations were performed at diagnosis (MRI-1), at mid-course of chemotherapy (MRI-2), and immediately before surgery (MRI-3). A DW sequence was performed using diffusion gradients of b0 and b900. The apparent diffusion coefficients (ADC1, ADC2, ADC3, respectively), their differentials (ADC2 - ADC1 and ADC3 - ADC1), and their variation (ADC2 - ADC1/ADC1 and ADC3 - ADC1/ADC1) were calculated for each of these three time points.
Fifteen patients were included. Patients with no increase in ADC showed a poor response to chemotherapy on their histology results. At mid-course, the three calculated values were significantly different between good and poor responders. ADC2 - ADC1 enabled us to detect, with 100% specificity, four out of seven of the poor responders. There was no significant difference in the values at MRI-3 between the two groups.
DW-MRI performed both at baseline and mid-course of neoadjuvant chemotherapy is an efficient method to predict further histological response of osteosarcoma. This method could be used as an early prognostic factor to monitor preoperative chemotherapy.
术前弥散加权磁共振成像(DW-MRI)已被描述为一种有效方法,可区分骨肉瘤患者化疗的良好和不良反应者。治疗过程中更早进行的 DW-MRI 有助于监测化疗。
评估 DW-MRI 在评估骨肉瘤化疗反应中的准确性,特别是在治疗中期。
本研究对接受长骨骨肉瘤治疗的青少年进行了前瞻性系列研究。在诊断时(MRI-1)、化疗中期(MRI-2)和手术前立即(MRI-3)进行磁共振检查。使用扩散梯度 b0 和 b900 进行 DW 序列。分别计算这三个时间点的表观扩散系数(ADC1、ADC2、ADC3)、它们的差异(ADC2-ADC1 和 ADC3-ADC1)以及它们的变化(ADC2-ADC1/ADC1 和 ADC3-ADC1/ADC1)。
共纳入 15 例患者。ADC 无增加的患者在组织学结果上对化疗反应不佳。在中期,良好和不良反应者之间的三个计算值有显著差异。ADC2-ADC1 能够以 100%的特异性检测到 7 个不良反应者中的 4 个。两组在 MRI-3 的值之间无显著差异。
在新辅助化疗的基线和中期进行 DW-MRI 是预测骨肉瘤进一步组织学反应的有效方法。该方法可用作监测术前化疗的早期预后因素。